Split Fed Circuit refuses Teva 'skinny label' ruling review

14-02-2022

Split Fed Circuit refuses Teva 'skinny label' ruling review

madamF / Shutterstock.com

A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline.


GSK, Coreg, carvedilol, Hatch-Waxman, skinny label, Federal Circuit, Teva, generics, patent infringement

LSIPR